Milestone Pharmaceuticals Inc. Common Shares MIST
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T01:24:37.983Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:04:51.550515951Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T01:24:37.611408+00:00
Milestone Pharmaceuticals Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 1.92 | 762.1% | 199.7% | |||
| 45Δ | 1.75 | 766.7% | 180.8% | 1.01 | 647.4% | 27.3% |
| 50Δ | 1.58 | 771.3% | 162.0% | 1.22 | 652.3% | 24.4% |
| 55Δ | 1.40 | 775.9% | 143.2% | 1.42 | 657.3% | 21.4% |
| 60Δ | 1.23 | 780.5% | 124.3% | 1.63 | 662.2% | 18.5% |
| 65Δ | 1.06 | 785.2% | 105.5% | 1.83 | 667.1% | 15.5% |
| 70Δ | 0.88 | 789.8% | 86.6% | 3.01 | 794.2% | 52.0% |
| 75Δ | 0.71 | 794.4% | 67.8% | 3.66 | 786.8% | 37.0% |
| 80Δ | 0.54 | 799.0% | 49.0% | 4.30 | 779.5% | 21.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 1.92
- IV
- 762.1%
- B/E move
- 199.7%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.75
- IV
- 766.7%
- B/E move
- 180.8%
- Pseudo strike
- 1.01
- IV
- 647.4%
- B/E move
- 27.3%
50Δ
- Pseudo strike
- 1.58
- IV
- 771.3%
- B/E move
- 162.0%
- Pseudo strike
- 1.22
- IV
- 652.3%
- B/E move
- 24.4%
55Δ
- Pseudo strike
- 1.40
- IV
- 775.9%
- B/E move
- 143.2%
- Pseudo strike
- 1.42
- IV
- 657.3%
- B/E move
- 21.4%
60Δ
- Pseudo strike
- 1.23
- IV
- 780.5%
- B/E move
- 124.3%
- Pseudo strike
- 1.63
- IV
- 662.2%
- B/E move
- 18.5%
65Δ
- Pseudo strike
- 1.06
- IV
- 785.2%
- B/E move
- 105.5%
- Pseudo strike
- 1.83
- IV
- 667.1%
- B/E move
- 15.5%
70Δ
- Pseudo strike
- 0.88
- IV
- 789.8%
- B/E move
- 86.6%
- Pseudo strike
- 3.01
- IV
- 794.2%
- B/E move
- 52.0%
75Δ
- Pseudo strike
- 0.71
- IV
- 794.4%
- B/E move
- 67.8%
- Pseudo strike
- 3.66
- IV
- 786.8%
- B/E move
- 37.0%
80Δ
- Pseudo strike
- 0.54
- IV
- 799.0%
- B/E move
- 49.0%
- Pseudo strike
- 4.30
- IV
- 779.5%
- B/E move
- 21.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 309.85% | |
| 318.53% | |
| 284.05% |
Biotechnology
MLTX
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery…
More →MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The…
More →MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →MPLT
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders.…
More →MRNA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases,…
More →MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →